Conversely, targets with minimal representation, such as helicases and spike glycoproteins, represent potential gaps in current research and may offer promising avenues for future drug discovery. Interestingly, the inclusion of compounds targeting less-studied (or reported in ChEMBL) viruses, such as HRV (487 compounds) and IBV (228 compounds), indicates a growing interest in broad-spectrum antiviral strategies.